Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 9:17 PM
Ignite Modification Date:
2025-12-24 @ 9:17 PM
NCT ID:
NCT03872804
Eligibility Criteria:
Inclusion Criteria:
* Adult patients (\>16 years old) of either gender having stable non segmental vitiligo, that is resistant to other lines of repigmentation therapy.
* Lack of progression of old lesions with the past 6 months.
* No development of new lesions
* Absence of history of koebner phenomenon.
* Absence of confetti lesions or hypopigmented lesions within the past 6 months.
* Presence of repigmentation of depigmented areas by medications or spontaneously in the past 6 months.
* While resistance to therapy will be judged after receiving standard protocol of NB-UVB together with oral mini pulse dexamethasone at a dose of 2.5 mg on two consecutive weekly days for 3 months.
* Patients having lesions showing absence or poor repigmentation after this regiment will be considered resistant to medical repigmentation and indicated to surgery.
Exclusion Criteria:
* Cases of active, progressive disease lacking criteria of stability previously mentioned.
* Patients with segmental or universal vitiligo covering more than 70% body surface area.
* Patients with known associated autoimmune diseases, bleeding tendency, current or history of skin neoplasia, photosensitive disorders or any contraindications to corticosteroids therapy.
* Patients with tendency towards hypertrophic scars or keloid formation.
* Pregnant female and lactating mothers.
* Patients with emotional and psychological instability.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
16 Years
Study:
NCT03872804
Study Brief:
Protocol Section:
NCT03872804